Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ACCD +3%
Other news:
- DOCU +5.6% (joining S&P MidCap 400)
- RLI +5% (estimates pretax catastrophe losses)
- PRCT +4% (receives FDA approval)
- ARMN +3.9% (reports Q3 production)
- CYH +3.8% (development partnership with Denim Health)
- OPT +3.2% (appoints Chief Medical Officer and Chief Financial Officer as company prepares for Phase 3 topline data readouts in 2025)
- NUVB +2.8% (names new CFO)
- SAM +2.6% (increases buyback program by $400 mln)
- MBUU +2.5% (discloses Settlement Agreement)
- CANF +2.5% (granted FDA orphan drug designation for treatment of pancreatic cancer)
- CDNA +2.3% (announces closure of DOJ investigation with no finding of wrongdoing)
- HON +2.1% (plans to spin-off Advanced Materials business to shareholders)
- MDU +2% (joining S&P SmallCap 600)
- PENN +1.9% (provides Q3 adjusted EBITDAR outlook)
- PTLO +1.2% (provides investor updates in presentation)